Trial Profile
A Phase 2a, Multi-Centre, Open-Label Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis on Non-head Locations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- Sponsors Peplin
- 12 Dec 2015 New trial record